OakChart

TherapeuticsMD Inc

TXMDHealthcare·Drug Manufacturers - Specialty & Generic·USA·Nano·NASD·Nov 11 • 3:58 PM ET

1.85+0.11 (6.32%)
2026-11-12 02:19 CET
Market cap
21.41 USD m
Revenue, TTM
3.27 USD m
Net income, TTM
-0.22 USD m
Free cash flow, TTM
3.12 USD m
EPS diluted, TTM
-0.02
P/E
-
Compare

Price

TXMD against its 20, 50 and 200-day averages
2050200
1.601.802.002.202.40130K260KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26TXMDclose 1.8520-day 1.8150-day 1.99200-day 2.091.85

37.3% under the 52-week high of 2.95 on 27 Jan 2026. 52-week low 1.36 on 11 Nov 2025. Last 15 sessions, 16.4% high to low

Volume 0.56× normal · the line is the 50-bar volume average

Profile

TXMD
52-week range, 31% of the way up
1.362.95

TherapeuticsMD, Inc. operates as a pharmaceutical company. The firm engages in licensing pharmaceutical products and collecting royalties. Its brands include BIJUVA, IMVEXXY, and ANNOVERA. The company was founded by Robert G. Finizio and Brian A. Bernick in 1907 and is headquartered in Boca Raton, FL.

Employees1
IPOJan 03, 2002
Beta0.63
ATR, 14d0.08
Rel volume0.56
Short float0.30%
Insider own8.45%
Inst own31.83%

Snapshot

6 groups

Valuation

Index-
Market Cap21.41M
Enterprise Value17.78M
Income-0.22M
Sales3.27M
Book/sh2.34
Cash/sh0.79
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees1
IPOJan 03, 2002

Ratios

P/E-
Forward P/E-
PEG-
P/S6.55
P/B0.79
P/C2.33
P/FCF6.86
EV/EBITDA-
EV/Sales5.44
Quick Ratio2.76
Current Ratio2.76
Debt/Eq0.20
LT Debt/Eq0.17
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.02
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y83.18% 72.84%
Sales past 3/5Y-64.91% -45.84%
EPS Y/Y TTM52.88%
Sales Y/Y TTM27.78%
EPS Q/Q-72.06%
Sales Q/Q-8.72%
EarningsAug 11 AMC
EPS/Sales Surpr.- -

Ownership

Insider Own8.45%
Insider Trans0.00%
Inst Own31.83%
Inst Trans-0.61%
ROA-0.78%
ROE-1.08%
ROIC-0.69%
Gross Margin49.36%
Oper. Margin-117.80%
Profit Margin-6.64%
SMA202.04%
SMA50-6.81%
SMA200-11.39%
Trades-

Technical

Shs Outstand11.57M
Shs Float10.60M
Short Float0.30%
Short Ratio1.30
Short Interest0.03M
52W High2.95 -37.29%
52W Low1.36 36.03%
Volatility6.15% 4.16%
ATR (14)0.08
RSI (14)49.48
Beta0.63
Rel Volume0.56
Avg Volume24.09K
Volume13,394

Performance

Perf Week1.65%
Perf Month-5.61%
Perf Quarter-11.06%
Perf Half Y-8.42%
Perf YTD13.50%
Perf Year13.15%
Perf 3Y-7.50%
Perf 5Y-94.39%
Perf 10Y-99.43%
Recom1.00
Target Price5.00
Prev Close1.74
Price1.85
Change %6.32%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Aug 07, 2020DowngradeJJefferiesHold → Underperform
May 19, 2020DowngradeJJP MorganOverweight → Neutral
Dec 02, 2019InitiatedGGuggenheimBuy
Oct 17, 2019InitiatedHH.C. WainwrightBuy$7+278.4%
Apr 30, 2019ResumedNNoble Capital MarketsOutperform$13+602.7%
Jun 15, 2018InitiatedJJP MorganOverweight$11+494.6%
Sep 08, 2017InitiatedMMorgan StanleyEqual-Weight$6+224.3%
Jul 11, 2017UpgradeOOppenheimerPerform → Outperform
May 09, 2017DowngradeOOppenheimerOutperform → Perform
Nov 22, 2016ResumedJJefferiesBuy$18+873.0%

Peers

Mkt cap
TickerCompanyMkt cap
AYTUAytu BioPharma Inc19.67M
DAREDare Bioscience Inc13.65M
RPRXRoyalty Pharma plc40.16B
LGNDLigand Pharmaceuticals Inc6.34B
LPCNLipocine Inc17.61M
CPIXCumberland Pharmaceuticals Inc91.70M
FEMYFemasys Inc12.57M
INVAInnoviva Inc1.34B
OGNOrganon & Co3.65B
XERSXeris Biopharma Holdings Inc3.02B

Insider trading

1 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Thompson Tommy GDirectorDec 23 '25Buy1.678,40014,03123,179Dec 29 04:23 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M
DXUVUS Vector Equity Portfolio ETF Class SharesAUM: 665.71M
DFACU.S. Core Equity 2 Portfolio-ETF Class SharesAUM: 49.14B
DFSUDimensional US Sustainability Core 1 ETFAUM: 2.38B
DCORUS Core Equity 1 Portfolio ETF Class SharesAUM: 3.65B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2025Q32025-11-12--0.013---
2025Q22025-08-12--0.048---
2025Q12025-05-13---0.057---
2024Q32024-11-12-0.050--0.0500.40--
2024Q22024-08-12-0.090--0.0950.40--
2024Q12024-05-10-0.070--0.0640.40--
2023Q42024-03-29-0.130--0.0770.40--
2023Q32023-11-14-0.130-0.150-0.316-0.501
2023Q22023-08-14-0.240-0.070-0.2360.400.501
2023Q12023-05-15-0.2400.060-0.3690.401.701
2022Q42023-04-108.3008.3008.3001.201.201
2022Q32022-11-14-3.130-0.570-3.12820.9226.80-
2022Q22022-08-1512.390-3.04012.39428.5023.201
2022Q12022-05-16-5.690-4.000-5.69118.9117.962
2021Q42022-03-10-5.000-3.833-5.02718.6829.393
2021Q32021-11-11-5.500-5.000-5.61624.4725.874

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2012FY-19.000--3.80-
2013FY-11.000-10.500-11.0008.788.43
2014FY-18.000-17.500-18.00015.0315.13
2015FY-24.500-24.625-24.50020.1419.80
2016FY-23.000-23.214-23.00019.3620.78
2017FY-18.500-17.986-18.50016.7817.58
2018FY-29.500-29.429-29.46716.1015.61
2019FY-36.000-34.860-35.75149.6546.97
2020FY-33.500-30.800-33.29062.8763.06
2021FY-21.500-20.167-21.66085.7897.28
2022FY0.120--10.34870.00-
2023FY-0.740--0.74070.00-

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2024Q3S2023-11-081002.302.302.30
2024Q3S2023-11-071002.302.302.30
2024Q3S2023-11-061002.302.302.30
2024Q3S2023-11-051002.302.302.30
2024Q3S2023-11-041002.302.302.30
2024Q3S2023-11-011002.302.302.30
2024Q3S2023-10-311002.302.302.30
2024Q3S2023-10-301002.302.302.30
2024Q3S2023-10-291002.302.302.30
2024Q3S2023-10-281002.302.302.30
2024Q3S2023-10-251002.302.302.30
2024Q3S2023-10-241002.302.302.30
2024Q3S2023-10-231002.302.302.30
2024Q3S2023-10-221002.302.302.30

Estimate history

EPS, annual-18.5-29.467-35.751-33.29-21.66-10.348-0.984-0.189-0.049-0.0189
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.095-0.0530.022-0.0570.0480.013-0.0540.0080.013
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual16.77816.09949.64764.8722.57369.9631.3021.7613.0223.27
Period201720182019202020212022202320242025TTM
Sales, quarterly0.2340.5470.6670.3930.9520.7840.8930.7240.869
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual4.3294.8095.4245.9958.5989.49811.53211.53211.57411.574
Period201720182019202020212022202320242025MRQ
Shares, quarterly11.53211.53211.53211.57411.57411.57411.57411.57411.574
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue3.273.021.761.3069.962.5764.8749.6516.10
Cost of Goods Sold Incl. D&A1.661.190.510.921.401.4017.026.953.03
Gross Profit1.611.831.250.3868.571.1747.8642.7013.07
Selling, General and Administrative Excl. Other5.476.044.748.9057.9080.75203.40193.90143.29
Research and Development0.000.000.000.000.000.0010.4319.7927.30
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-3.85-4.21-3.49-8.5210.66-79.58-155.54-151.21-130.22
Interest Expense0.000.010.010.200.0032.9228.5817.384.68
Unusual Expense0.100.181.270.009.470.000.0010.06-
Net Income Before Taxes-0.26-0.65-2.34-7.741.07-79.31-183.52-176.14-132.62
Income Taxes0.030.00-0.03-0.040.000.000.000.000.00
Consolidated Net Income-0.29-0.65-2.31-7.701.07-79.31-183.52-176.14-132.62
Net Income From Continuing Operations-0.29-0.65-2.31-7.701.07-79.31-183.52-176.14-132.62
Net Income-0.22-0.57-2.18-10.28-93.42-172.41-183.52-176.14-132.62
EPS (Recurring)-0.01-0.04-0.11-0.98-9.61-21.66-33.29-34.32-29.47
EPS (Basic, Before Extraordinaries)-0.02-0.05-0.19-0.98-10.35-21.66-33.29-35.75-29.47
EPS (Diluted)-0.02-0.05-0.19-0.98-10.35-21.66-33.29-35.75-29.47
EBITDA-2.20-3.02-2.98-7.6011.86-78.84-150.07-148.75-129.93
Non-Operating Income (Expense)3.693.752.430.98-0.120.270.602.502.28
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.060.070.211.0011.5718.1210.6810.688.66
Price To Sales Ratio7.876.245.6318.040.7254.995.1412.0153.25
Gross Margin49.3660.5271.1029.1998.0045.5173.7786.0181.17
Operating Margin-117.80-139.44-198.30-654.6115.24-3,092.77-239.76-304.56-808.85
Net Margin-6.64-18.83-123.85-789.40-133.52-6,700.93-282.90-354.80-823.74
Shares Outstanding11.5711.5711.5311.539.508.606.005.424.81
Market Capitalization21.4121.419.9223.7952.92152.82362.72656.25916.16

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.870.720.890.780.950.390.670.55
Cost of Goods Sold Incl. D&A0.330.330.910.100.100.100.100.10
Gross Profit0.540.40-0.010.690.860.300.570.45
Selling, General and Administrative Excl. Other1.341.121.481.521.551.080.881.31
Research and Development0.000.000.000.000.000.000.00-
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-0.80-0.72-1.50-0.83-0.69-0.78-0.31-0.86
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.010.000.060.030.000.090.010.00
Net Income Before Taxes0.160.10-0.580.050.55-0.670.08-0.57
Income Taxes0.000.000.030.000.00-0.03-0.030.00
Consolidated Net Income0.160.10-0.610.050.55-0.640.11-0.57
Net Income From Continuing Operations0.160.10-0.610.050.55-0.640.11-0.57
Net Income0.150.10-0.620.150.55-0.650.25-0.61
EPS (Recurring)0.010.01-0.050.020.05-0.050.02-0.05
EPS (Basic, Before Extraordinaries)0.010.01-0.050.010.05-0.060.02-0.05
EPS (Diluted)0.010.01-0.050.010.05-0.060.02-0.05
EBITDA-0.47-0.40-0.59-0.73-0.60-0.69-0.21-0.76
Non-Operating Income (Expense)0.980.830.970.921.240.200.400.29
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.000.000.060.000.000.020.020.03
Price To Earnings Ratio--62.45-----
Price To Sales Ratio7.877.016.244.455.255.805.6311.99
Gross Margin62.1455.11-1.4687.7689.9275.8385.0182.45
Operating Margin-92.41-99.86-167.53-105.87-73.00-199.24-46.78-157.04
Net Margin17.8413.12-69.3219.3957.88-166.1637.78-111.33
Shares Outstanding11.5711.5711.5711.5711.5711.5711.5311.53
Market Capitalization21.4123.3818.8712.4413.4310.679.9219.14

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments7.485.064.3349.3264.9180.49160.83161.61127.14
Short Term Receivables3.523.563.090.000.0032.3824.4011.064.33
Inventories0.000.000.000.000.007.9911.863.271.49
Other Current Assets1.101.302.043.7052.267.5410.788.946.60
Total Current Assets12.119.939.4653.02117.16128.40207.87184.88139.55
Net Property, Plant & Equipment5.296.106.877.669.0611.5112.620.470.44
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Long-Term Note Receivable13.7116.0118.4820.250.00----
Intangible Assets3.764.326.106.947.1441.4444.4824.093.10
Other Assets2.782.462.392.5936.110.251.022.540.14
Total Assets37.6638.8243.3190.46169.47181.61265.99211.98143.23
Short Term Debt Incl. Current Port. of LT Debt0.971.631.471.39189.632.251.500.000.00
Accounts Payable0.380.260.032.163.3721.0719.1822.744.10
Other Current Liabilities3.433.275.3543.2959.8935.9232.3218.339.22
Total Current Liabilities4.795.176.8546.84252.8959.2453.0041.0813.32
Long Term Debt5.125.546.537.378.06246.37203.7873.380.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.870.740.641.112.140.000.000.000.00
Total Liabilities10.7811.4514.0255.31263.09305.61256.78114.4613.32
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity26.8827.3729.2935.14-93.62-124.009.2097.52129.91
Total Shareholders Equity26.8827.3729.2935.14-93.62-124.009.2097.52129.91
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity26.8827.3729.2935.14-93.62-124.009.2097.52129.91
Total Liabilities & Stockholders Equity37.6638.8243.3190.46169.47181.61265.99211.98143.23
Book Value Per Share2.322.372.543.70-10.89-20.681.7020.2830.01
Tangible Book Value Per Share2.002.002.012.97-11.72-27.60-6.5015.2729.30
Full-Time Employees1111416400348241173
Price to Book Ratio0.790.370.85-1.90-1.63-2.9371.329.398.74
Return on Assets-1.71-5.63-11.510.83-45.18-82.00-73.71-74.67-53.85
Return on Equity-2.41-8.16-23.90----330.09-116.62-59.77
Return on Invested Capital-1.78-6.63-28.69-219.75--149.97-82.70-77.60-59.21
Quick Ratio2.531.921.381.130.462.033.704.4210.36
Current Ratio2.531.921.381.130.462.173.924.5010.48

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-0.22-0.57-2.18-10.28112.00-172.41-183.52-176.14-132.62
Depreciation1.661.190.510.921.190.745.472.450.29
Other Funds (Non Cash)-0.270.140.74-21.34-113.1819.2821.9021.999.15
Funds from Operations1.170.76-0.93-30.700.01-152.40-156.15-151.70-123.18
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital1.951.661.66-17.45-4.094.59-3.32-14.0016.36
Cash from Operating Activities3.122.420.73-48.14-4.08-147.81-159.47-165.70-106.81
Capital Expenditures0.000.000.000.00-0.35-2.22-1.60-23.89-21.32
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.00-0.02-0.18
Other Sources0.000.000.000.00223.830.000.000.00-
Cash from Investing Activities0.000.000.000.00223.48-2.22-1.60-23.91-21.50
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.000.000.003.15-14.51184.6731.9777.1491.57
Repurchase of Common Pref Stock0.000.000.000.00-38.660.000.000.000.00
Sale of Common Pref Stock0.000.000.003.1524.15184.6731.9777.1491.57
Proceedsfrom Stock Options0.000.000.003.1524.15184.3531.7077.0389.91
Issuance or Reduction of Debt, Net0.000.000.000.00-219.43-50.0048.75111.6971.21
Change in Long Term Debt0.000.000.000.00-219.43-50.0048.75111.6971.21
Issuance of Long Term Debt0.000.000.000.000.000.0048.75193.3571.21
Reduction of Long Term Debt0.000.000.000.00-219.43-50.000.00-81.660.00
Net Financing Active Other Cash Flow0.000.000.000.000.350.000.000.000.00
Other Financing Activities Uses0.000.000.000.00-2.970.000.000.000.00
Cash from Financing Activities0.000.000.003.15-235.21134.6780.72188.83162.79
Net Change in Cash3.122.420.73-44.99-15.80-15.36-80.34-0.7834.48
Free Cash Flow3.122.420.73--4.08-147.84-159.68-168.15-107.03
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow8.257.7813.55------
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments9.198.427.487.126.075.75
Short Term Receivables3.393.213.523.673.743.00
Inventories0.000.000.000.000.000.00
Other Current Assets1.201.301.101.391.311.44
Total Current Assets13.7912.9312.1112.1711.1310.18
Net Property, Plant & Equipment4.835.065.295.515.735.95
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets3.563.673.763.914.044.14
Other Assets2.732.752.782.802.762.54
Total Assets37.5337.5837.6638.6738.5038.24
Short Term Debt Incl. Current Port. of LT Debt1.041.010.971.070.891.01
Accounts Payable0.460.010.380.260.350.18
Other Current Liabilities3.503.893.433.613.433.55
Total Current Liabilities5.004.914.794.954.664.74
Long Term Debt4.524.825.125.415.725.96
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.870.870.870.870.830.80
Total Liabilities10.4010.6110.7811.2311.2111.50
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity27.1326.9726.8827.4427.2926.74
Total Shareholders Equity27.1326.9726.8827.4427.2926.74
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity27.1326.9726.8827.4427.2926.74
Total Liabilities & Stockholders Equity37.5337.5837.6638.6738.5038.24
Book Value Per Share2.342.332.322.372.362.31
Tangible Book Value Per Share2.042.012.002.032.011.95
Full-Time Employees11111-
Price to Book Ratio0.790.870.690.460.500.39
Return on Assets-0.780.23-1.710.19-1.38-5.33
Return on Equity-1.080.32-2.410.27-1.98-7.72
Return on Invested Capital0.490.30-1.930.461.67-2.00
Quick Ratio2.762.632.532.462.392.15
Current Ratio2.762.632.532.462.392.15

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income0.150.10-0.620.150.55-0.65
Depreciation0.330.330.910.100.100.10
Other Funds (Non Cash)0.020.00-0.480.190.150.27
Funds from Operations0.500.42-0.190.440.80-0.29
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.270.510.560.60-0.480.97
Cash from Operating Activities0.770.940.371.050.320.69
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.000.000.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.000.000.000.000.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.000.000.000.000.000.00
Net Change in Cash0.770.940.371.050.320.69
Free Cash Flow0.770.940.371.050.320.69
Price to Free Cash Flow8.258.797.786.0216.047.59

Revenue breakdown

Total Pharmaceutical Preparations revenue2024: 1.76M 2025: 3.02M
Non-US2024: 638.00K 2025: 1.23M
United States2024: 1.12M 2025: 1.79M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.30%0.0M10.6M23.47K
2026-10-150.23%0.0M10.6M23.70K
2026-09-300.22%0.0M10.6M25.37K
2026-09-150.25%0.0M10.6M28.57K
2026-08-310.25%0.0M10.6M42.20K
2026-08-140.26%0.0M10.6M36.89K
2026-07-310.27%0.0M10.8M38.31K
2026-07-150.40%0.0M10.8M38.42K
2026-06-300.52%0.1M10.8M37.61K
2026-06-150.43%0.0M10.8M35.15K
2026-05-290.48%0.1M10.8M21.80K
2026-05-150.49%0.1M10.8M22.70K
2026-04-300.53%0.1M10.8M27.08K
2026-04-150.48%0.1M10.8M47.78K
2026-03-310.42%0.0M11.4M76.13K
2026-03-130.42%0.0M11.4M81.93K
2026-02-270.40%0.0M11.4M87.94K
2026-02-130.41%0.0M11.4M114.48K
2026-01-300.42%0.0M11.4M129.87K
2026-01-150.77%0.1M11.4M263.22K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.000.501.350.8211.3102.000.000.891-0.0350.001
call2.000.000.550.105.35551.000.000.627-0.0330.001
call3.000.000.350.055.5581.000.000.450-0.0360.001
call4.000.001.000.006.6930.000.000.413-0.0430.001
call5.000.001.600.007.4850.000.000.393-0.0470.001
put1.000.002.150.0015.6270.000.00-0.071-0.0340.000
put2.000.000.700.273.5791.000.00-0.485-0.0180.001
put3.000.851.700.007.3290.000.00-0.618-0.0290.001
put4.001.852.550.007.1700.000.00-0.587-0.0420.001
put5.002.703.600.008.4160.000.00-0.607-0.0460.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-118-KCurrent report2026-08-11SEC
2026-08-05SCHEDULE 13G/ASEC
2026-05-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-128-KCurrent report2026-05-02SEC
2026-04-06SCHEDULE 13GSEC
2026-04-0110-K/A2025-12-31SEC
2026-04-01NT 10-K2025-12-31SEC
2026-03-308-KCurrent report2026-03-30SEC
2026-03-3010-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-01-218-KCurrent report2026-01-15SEC
2025-12-294Statement of changes in beneficial ownership of securities2025-12-23SEC
2025-12-168-KCurrent report2025-12-15SEC
2025-11-138-KCurrent report2025-11-12SEC
2025-11-1210-QQuarterly report pursuant to Section 13 or 15(d)2025-09-30SEC
2025-11-054Statement of changes in beneficial ownership of securities2025-11-03SEC
2025-11-054Statement of changes in beneficial ownership of securities2025-11-03SEC
2025-11-054Statement of changes in beneficial ownership of securities2025-11-03SEC
2025-11-054Statement of changes in beneficial ownership of securities2025-11-03SEC
2025-11-03ARSAnnual report to security holders. 2024-12-31SEC
2025-11-03DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2025-11-03DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342025-12-15SEC
2025-10-24PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342025-10-24SEC
2025-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2025-06-30SEC
2025-08-128-KCurrent report2025-08-12SEC
2025-05-1310-QQuarterly report pursuant to Section 13 or 15(d)2025-03-31SEC
2025-05-138-KCurrent report2025-05-13SEC
2025-04-3010-K/A2024-12-31SEC
2025-04-154Statement of changes in beneficial ownership of securities2025-04-14SEC
2025-04-154Statement of changes in beneficial ownership of securities2025-04-14SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-1214.03K100
2025-110000

Institutional holders

Manager% owned
Rubric Capital Management LP10.30%
Clearline Capital LP5.49%
VANGUARD CAPITAL MANAGEMENT LLC3.06%
ADAR1 Capital Management, LLC2.96%
Tejara Capital Ltd2.83%
RENAISSANCE TECHNOLOGIES LLC1.27%
MORGAN STANLEY1.12%
BlackRock, Inc.0.99%
GEODE CAPITAL MANAGEMENT, LLC0.92%
CITADEL ADVISORS LLC0.74%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.11%
VANGUARD EXTENDED MARKET INDEX FUND0.95%
Fidelity Extended Market Index Fund0.52%
Ultra-Small Company Market Fund0.15%
Fidelity Series Total Market Index Fund0.13%
Fidelity Total Market Index Fund0.13%
Dimensional U.S. Core Equity 2 ETF0.04%
Dimensional US Sustainability Core 1 ETF0.03%
The Gabelli ABC Fund0.03%
Dimensional US Core Equity 1 ETF0.03%

OakChart. TXMD. Cached 15 minutes.